What is HC Wainwright’s Forecast for BHST FY2026 Earnings?

BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a research note issued on Monday, November 16th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($0.62) for the year, down from their previous estimate of ($0.59). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q4 2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.11 EPS, FY2029 earnings at $0.56 EPS and FY2030 earnings at $1.12 EPS.

A number of other analysts have also weighed in on BHST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Monday, September 14th. Maxim Group cut their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Finally, Roth Capital reduced their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BioHarvest Sciences presently has an average rating of “Hold” and a consensus target price of $6.50.

Read Our Latest Research Report on BHST

BioHarvest Sciences Price Performance

Shares of BHST stock opened at $1.22 on Wednesday. The company has a market capitalization of $23.94 million, a P/E ratio of -2.30 and a beta of 0.93. The company’s 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $3.04. BioHarvest Sciences has a one year low of $0.91 and a one year high of $7.20.

BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $7.87 million during the quarter, compared to the consensus estimate of $9.31 million. BioHarvest Sciences had a negative net margin of 34.67% and a negative return on equity of 55.88%.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in BioHarvest Sciences stock. TD Waterhouse Canada Inc. boosted its position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) by 83.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,827 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. TD Waterhouse Canada Inc. owned 0.22% of BioHarvest Sciences worth $64,000 at the end of the most recent quarter.

BioHarvest Sciences Company Profile

(Get Free Report)

BioHarvest Sciences Inc. is a biotechnology company that develops plant-based ingredients and consumer products using its proprietary Botanical Synthesis platform. The technology grows selected plant cells in controlled bioreactors, offering an alternative to cultivating and processing whole plants. The company’s best-known product is VINIA, a dietary supplement made from red grape cells. BioHarvest also works to develop additional botanical ingredients and products for consumer markets, including nutraceuticals and cosmetics.

Featured Articles

Earnings History and Estimates for BioHarvest Sciences (NASDAQ:BHST)

Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.